ICGT ICG Enterprise Trust

Hardman Talks: ICG Enterprise Trust webinar

Hardman & Co Research
Hardman Talks: ICG Enterprise Trust webinar

08-Oct-2020 / 07:00 GMT/BST


Hardman Talks | ICG Enterprise Trust live webinar

A webinar presentation will be given by the ICG Enterprise Trust management team on Thursday 15 October at 3pm. On the webinar will be ICG Head of PE Fund Investments, Oliver Gardey and Managing Director, Colm Walsh.

 

The webinar is being hosted by Hardman & Co and investors can register to attend via this link:

 

This webinar represents a key communication channel for investors to keep up to date with the company's strategy and progress. All investors, whether existing shareholders or not, are invited to watch the presentation and take part in the Q&A session afterwards. There is no charge for attending. Investors are encouraged to submit their questions when registering or during the event.

 

A recording of the webinar will be available on the Hardman & Co website shortly after the event for those could not attend the live presentation.

If you are interested in meeting the company, you can register your interest on our website .

To contact us:

Hardman & Co
35 New Broad Street
London
EC2M 1NH

 

Follow us on Twitter @HardmanandCo

Contact:

Mark Thomas

2

 


 

 

Hardman & Co Research can still be accessed for free after MiFID II.
Please to read the statement.

About Hardman & Co: For the past 25 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge.  Our focus is to raise companies' profiles across the UK and abroad with outstanding research, investor engagement programmes and advisory services. Some of our notes have been commissioned by the company which is the subject of the note; this is clearly stated in the disclaimer where this is the case.

Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.

Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies.  It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer.



Dissemination of a CORPORATE NEWS, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.


End of Announcement - EQS News Service

1139544  08-Oct-2020 

fncls.ssp?fn=show_t_gif&application_id=1139544&application_name=news&site_id=research_pool
EN
08/10/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ICG Enterprise Trust

 PRESS RELEASE

Director/PDMR Shareholding

Director/PDMR Shareholding ICG Enterprise Trust plc (the “Company”) 2 April 2026 Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them The Company received notification on 1 April 2026 that Jane Tufnell, Chair, transferred 13,283 ordinary shares in the Company ("Shares") from a General Investment Account (“GIA”) to an Individual Savings Account (“ISA”), and that she transferred 6,380 Shares to a person closely associated (“PCA”) with her, who subsequently transferred those 6,380 Shares from a GIA to ...

Mark Thomas ... (+3)
  • Mark Thomas
  • Martin Hall
  • Mike Foster

Hardman & Co Monthly: April 2026

Feature article: 2025 pharma statistics, by Dr Martin Hall, Head of Life Sciences at Hardman & Co Our pharmaceutical dataset has been compiled over 40 years from 109 companies, which, through M&A activity and consolidation, now comprise 46 companies. An efficient reporting system has seen all the listed multinational pharma companies announce results for 2025, giving us the opportunity to update our industry statistics and drug database. This report provides the first snapshot of global pharmac...

 PRESS RELEASE

Voting Rights and Capital

Voting Rights and Capital ICG Enterprise Trust plc (the “Company”) 1 April 2026 Total Voting Rights In accordance with the FCA's Disclosure Guidance and Transparency Rule 5.6.1R, the Company announces as follows. At the close of business on 31 March 2026, the Company had 63,554,192 Ordinary shares in issue, of which 2,074,106 were held in Treasury. Therefore, the total number of voting rights in the Company is 61,480,086.The above figure 61,480,086 may be used by Shareholders as the denominator for the calculations by which they will determine if they are required to notify their intere...

 PRESS RELEASE

Transaction in Own Shares

Transaction in Own Shares ICG Enterprise Trust plc (the “Company”) 31 March 2026 Transaction in Own Shares The Company announces that on 30 March 2026 it bought back 15,000 of its own shares, to be held as treasury shares, at an average price of 1330 pence per share. Further details are set out below: Number of shares held as treasury shares following settlement of this purchase: 2,089,106Total shares in issue excluding treasury shares following settlement of this purchase: 61,465,086 The Company has bought back these shares under the authority granted by shareholders at i...

 PRESS RELEASE

Transaction in Own Shares

Transaction in Own Shares ICG Enterprise Trust plc (the “Company”) 25 March 2026 Transaction in Own Shares The Company announces that on 24 March 2026 it bought back 15,000 of its own shares, to be held as treasury shares, at an average price of 1327 pence per share. Further details are set out below: Number of shares held as treasury shares following settlement of this purchase: 2,074,106Total shares in issue excluding treasury shares following settlement of this purchase: 61,480,086 The Company has bought back these shares under the authority granted by shareholders at its Annual Ge...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch